Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$0.99
-5.7%
$1.26
$0.90
▼
$2.98
$108.50M2.381.39 million shs1.72 million shs
Evotec AG stock logo
EVO
Evotec
$1.33
-8.3%
$1.57
$1.33
▼
$3.87
$473.24M2.0199,825 shs73,709 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.12
-2.5%
$1.97
$0.84
▼
$4.31
$269.39M0.662.15 million shs5.06 million shs
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$18.50
$18.48
$11.09
▼
$21.01
$374.16M1.31253,980 shsN/A
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-8.70%+9.59%-14.63%-37.13%-35.19%
Evotec AG stock logo
EVO
Evotec
-0.68%-12.65%-2.03%-24.87%-51.51%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-10.70%-8.82%-14.90%+127.34%-9.96%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
0.00%0.00%0.00%+0.54%+13.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$0.99
-5.7%
$1.26
$0.90
▼
$2.98
$108.50M2.381.39 million shs1.72 million shs
Evotec AG stock logo
EVO
Evotec
$1.33
-8.3%
$1.57
$1.33
▼
$3.87
$473.24M2.0199,825 shs73,709 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.12
-2.5%
$1.97
$0.84
▼
$4.31
$269.39M0.662.15 million shs5.06 million shs
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$18.50
$18.48
$11.09
▼
$21.01
$374.16M1.31253,980 shsN/A
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-8.70%+9.59%-14.63%-37.13%-35.19%
Evotec AG stock logo
EVO
Evotec
-0.68%-12.65%-2.03%-24.87%-51.51%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-10.70%-8.82%-14.90%+127.34%-9.96%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
0.00%0.00%0.00%+0.54%+13.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Codexis, Inc. stock logo
CDXS
Codexis
2.40
Hold$6.00506.06% Upside
Evotec AG stock logo
EVO
Evotec
2.00
Hold$3.50163.16% Upside
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
2.60
Moderate Buy$3.8381.25% Upside
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
1.83
Reduce$17.25-6.76% Downside

Current Analyst Ratings Breakdown

Latest CDXS, EVO, SLP, and NAUT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Codexis, Inc. stock logo
CDXS
Codexis
Reiterated RatingOverweight$5.00
11/6/2026
Evotec AG stock logo
EVO
Evotec
Boost Price TargetBuy$4.00 ➝ $5.00
10/28/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
UpgradeSell (E+) ➝ Sell (D)
10/23/2026
Codexis, Inc. stock logo
CDXS
Codexis
UpgradeSell (E+) ➝ Sell (D-)
10/14/2026
Evotec AG stock logo
EVO
Evotec
Reiterated RatingBuy$4.00
10/9/2026
Codexis, Inc. stock logo
CDXS
Codexis
DowngradeSell (D-) ➝ Sell (E+)
10/7/2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
Dropped CoverageNeutral
10/6/2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
Reiterated RatingSell (D+)
9/30/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
UpgradeHold
9/29/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Initiated CoverageBuy$3.50
9/29/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
UpgradeStrong-Buy
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Codexis, Inc. stock logo
CDXS
Codexis
$70.39M1.54N/AN/A$0.47 per share2.11
Evotec AG stock logo
EVO
Evotec
$891.97M0.53N/AN/A$2.08 per share0.64
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/A$0.92 per shareN/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$82.06M4.56$1.43 per share12.93$6.20 per share2.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Codexis, Inc. stock logo
CDXS
Codexis
-$43.97M-$0.20N/AN/AN/A-21.77%-43.24%-14.21%N/A
Evotec AG stock logo
EVO
Evotec
-$117.12MN/AN/A33.25N/A-26.20%-24.93%-11.35%N/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$59M-$0.46N/AN/AN/AN/A-42.68%-34.39%N/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
-$64.72M$0.4046.25N/AN/A9.88%13.50%12.45%12/7/2026 (Estimated)

Latest CDXS, EVO, SLP, and NAUT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/7/2026Q4 2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$0.14N/AN/AN/A$19.18 millionN/A
11/12/2026Q3 2026
Codexis, Inc. stock logo
CDXS
Codexis
-$0.0957-$0.08+$0.0157-$0.08$18.72 million$19.26 million
10/27/2026Q3 2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.14-$0.12+$0.02-$0.12$0.21 million$0.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/AN/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$0.241.30%-100.00%60.00%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Codexis, Inc. stock logo
CDXS
Codexis
0.58
2.81
2.99
Evotec AG stock logo
EVO
Evotec
0.65
2.32
2.19
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/A
9.25
9.25
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
N/A
5.54
5.54

Institutional Ownership

CompanyInstitutional Ownership
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
Evotec AG stock logo
EVO
Evotec
5.81%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
50.71%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
78.08%

Insider Ownership

CompanyInsider Ownership
Codexis, Inc. stock logo
CDXS
Codexis
3.50%
Evotec AG stock logo
EVO
Evotec
1.00%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
41.10%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
19.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Codexis, Inc. stock logo
CDXS
Codexis
146109.60 million105.76 millionOptionable
Evotec AG stock logo
EVO
Evotec
4,553355.82 million352.26 millionNot Optionable
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
130127.37 million75.02 millionOptionable
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
16020.23 million16.36 millionOptionable

Recent News About These Companies

Altaris Completes Acquisition of Simulations Plus

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Codexis stock logo

Codexis NASDAQ:CDXS

$0.99 -0.06 (-5.71%)
As of 03:46 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Evotec stock logo

Evotec NASDAQ:EVO

$1.33 -0.12 (-8.28%)
Closing price 03:58 PM Eastern
Extended Trading
$1.32 -0.02 (-1.13%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Nautilus Biotechnology stock logo

Nautilus Biotechnology NASDAQ:NAUT

$2.12 -0.06 (-2.53%)
Closing price 03:58 PM Eastern
Extended Trading
$2.12 +0.00 (+0.24%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Simulations Plus stock logo

Simulations Plus NASDAQ:SLP

$18.50 0.00 (0.00%)
As of 11/6/2026

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.